It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
CADASIL is a small vessel disease caused by mutations in NOTCH3 that lead to an odd number of cysteines in the EGF-like repeat domain, causing protein misfolding and aggregation. The main symptoms are migraine, psychiatric disturbances, recurrent strokes and dementia, being executive function characteristically impaired. The molecular pathways altered by this receptor aggregation need to be studied further. A genome-wide transcriptome study (four cases paired with three healthy siblings) was carried out, in addition to a qRT-PCR for validation purposes (ten new cases and eight new controls). To study the expression profile by cell type of the significant mRNAs found, we performed an in situ hybridization (ISH) (nine cases and eight controls) and a research in the Single-nuclei Brain RNA-seq expression browser (SNBREB). Pathway analysis enrichment was carried out with Gene Ontology and Reactome. Neuropsychological tests were performed in five of the qRT-PCR cases. The two most significant differentially expressed mRNAs (BANP, p-value = 7.23 × 10–4 and PDCD6IP, p-value = 8.36 × 10–4) were selected for the validation study by qRT-PCR. Additionally, we selected two more mRNAs (CAMK2G, p-value = 4.52 × 10–3 and E2F4, p-value = 4.77 × 10–3) due to their association with ischemic neuronal death. E2F4 showed differential expression in the genome-wide transcriptome study and in the qRT-PCR (p = 1.23 × 10–3), and it was upregulated in CADASIL cases. Furthermore, higher E2F4 expression was associated with worse executive function (p = 2.04 × 10–2) and attention and information processing speed (IPS) (p = 8.73 × 10–2). In situ hibridization showed E2F4 expression in endothelial and vascular smooth vessel cells. In silico studies indicated that E2F4 is also expressed in brain endothelial cells. Among the most significant pathways analyzed, there was an enrichment of vascular development, cell adhesion and vesicular machinery terms and autophagy process. E2F4 is more highly expressed in the skin biopsy of CADASIL patients compared to controls, and its expression is present in endothelial cells and VSMCs. Further studies are needed to understand whether E2F4 could be useful as a biomarker, to monitor the disease or be used as a therapeutic target.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Institut de Recerca de l`Hospital de la Santa Creu i Sant Pau, Stroke Pharmacogenomics and Genetics Group, Barcelona, Spain (GRID:grid.413396.a) (ISNI:0000 0004 1768 8905)
2 Vall d’Hebron Institute of Research, Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Neurovascular Research Laboratory, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)
3 Institut de Recerca de l`Hospital de la Santa Creu i Sant Pau, Stroke Pharmacogenomics and Genetics Group, Barcelona, Spain (GRID:grid.413396.a) (ISNI:0000 0004 1768 8905); Fundació MútuaTerrassa per la Docència i la Recerca, Stroke Pharmacogenomics and Genetics, Terrassa, Spain (GRID:grid.413396.a)
4 Fundació MútuaTerrassa per la Docència i la Recerca, Stroke Pharmacogenomics and Genetics, Terrassa, Spain (GRID:grid.413396.a); The Manchester Metropolitan University of All Saints, Manchester, UK (GRID:grid.25627.34) (ISNI:0000 0001 0790 5329)
5 Hospital del Mar-Parc de Salut Mar, Dermatology Department, Barcelona, Spain (GRID:grid.418476.8)
6 IMIM-Hospital del Mar, Neurology Department, Barcelona, Spain (GRID:grid.416319.8)
7 Hospital Mútua Terrassa, Neurology Department, Terrassa, Spain (GRID:grid.414875.b) (ISNI:0000 0004 1794 4956)
8 Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB-Sant Pau), Neurology Department, Barcelona, Spain (GRID:grid.413396.a) (ISNI:0000 0004 1768 8905)
9 The Manchester Metropolitan University of All Saints, Manchester, UK (GRID:grid.25627.34) (ISNI:0000 0001 0790 5329); Biomedicine Institute of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC, University of Seville, Seville, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229); Hospital Universitario Virgen Macarena, Department of Neurology, Seville, Spain (GRID:grid.411375.5) (ISNI:0000 0004 1768 164X)